$PHAR News
Last published 1d ago
- 1d agoPHARPharming to participate in fireside chat at Jefferies Global Healthcare Conference in LondonGlobeNewswirePharming to participate in fireside chat at Jefferies Global Healthcare Conference in London on Wednesday Nov. 18 at 9:30 am GMT. Webcast will be available
- 6d agoPHARMHRA approves Pharming’s Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K.GlobeNewswireApproval extends existing U.K. indication for Joenja to eligible children aged 4 to 11 who weigh at least 27 kgJoenja is expected to become available to patients covered by the expanded indication in February 2027Marks
- 6d agoPHARMHRA approves Pharming’s Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K.GlobeNewswireMHRA approves Pharming’s Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K. Approval extends existing U.K....
- 2w agoPHARPharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in NovemberGlobeNewswireThird quarter 2026 total revenues increased by 21% to US$117.6 million, compared to third quarter 2025, exceeding market expectationsRUCONEST® revenue increased by 14% to US$93.8 million, compared to third quarter 2025,
- 3w agoPHARPharming Group announces third quarter 2026 revenues above market expectationsGlobeNewswireThird quarter 2026 total revenues increase by 21% to approximately US$117.6 million, compared to third quarter 2025Third quarter 2026 total operating expenses of approximately US$74.6 million, in line with third quarter
- 4w agoPHARPharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026GlobeNewswireFirst clinical data for leniolisib in a larger group of PID participants beyond APDS, supporting the potential of targeted PI3Kδ inhibition to address immune dysregulationLeniolisib was well-tolerated, with benefits
- 1mo agoPHARMPHARPharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026GlobeNewswireLeniolisib was generally well-tolerated, with clinical improvements across multiple measures of immune dysregulation, including reductions in lymphoproliferation Separately, Pharming expects to report topline results
- 2mo agoPHARMPHARFDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.GlobeNewswireFDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) ages 4 to 11 who weigh at least 27kgNewly approved Joenja doses are expected to be
- 2mo agoPHARMPHARPharming Group to participate in September investor conferencesGlobeNewswireLeiden, the Netherlands, September 9, 2026: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) today announced that its management will participate in the following investor conferences in the month of September:
- 3mo agoPHARMPHARPharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and olderGlobeNewswireLaunch marks first commercial availability of Joenja® (leniolisib) for children aged 4 to 11 worldwide OrphanPacific, Inc. serves as Marketing Authorization holder and is responsible for supply and distribution in Japan
- 3mo agoPHARMPHARPharming Group to participate in Canaccord Genuity 46th Annual Growth ConferenceGlobeNewswireLeiden, the Netherlands, August 4, 2026: Pharming Group N.V. (NASDAQ:PHAR), today announced its participation in the Canaccord Genuity 46th Annual Growth Conference in Boston on August 12-13, 2026. Michael Levitan, VP
- 3mo agoPHARMPHARPharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic useGlobeNewswireFor investor audiences and media only Second quarter 2026 total revenues decreased by 3% to US$90.2 million, compared to the second quarter 2025RUCONEST® revenue was US$72.3 million, a 10% decrease compared to the
- 3mo agoPHARMPHARPharming Group to report second quarter and first half 2026 financial results and provide business update on July 30GlobeNewswireLeiden, the Netherlands, July 16, 2026: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) confirms that it will report its preliminary (unaudited) financial results for the second quarter and first half 2026 and
- 5mo agoPHARPharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDSGlobeNewswireIf approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency Supplemental New Drug Application
- 5mo agoPHARPharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New YorkGlobeNewswireLeiden, the Netherlands, June 2, 2026: Pharming Group ("Pharming") (NASDAQ:PHAR) today announced its participation in the 2026 Jefferies Global Healthcare Conference in New York on June 3-4, 2026. Fabrice Chouraqui,
- 5mo agoPHAREuropean Commission grants marketing authorization to Pharming's Joenja® (leniolisib) – the first approved treatment for APDS in the European UnionGlobeNewswireJoenja® (leniolisib) is first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency, in adult and pediatric patients aged 12
- 6mo agoPHARPharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disordersGlobeNewswireLeiden, the Netherlands, May 7, 2026: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) today announced presentations at the 2026 Annual Meeting of the Clinical Immunology Society (CIS), taking place May
- 6mo agoPHARPharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026GlobeNewswireFirst quarter 2026 total revenues were US$72.4 million, an 8% decrease compared to the first quarter 2025RUCONEST® revenue was US$58.4 million, a 15% decrease compared to the first quarter 2025, mainly due to
- 6mo agoPHARPharming Group to report first quarter 2026 financial results and provide business update on May 7GlobeNewswireLeiden, the Netherlands, April 23, 2026: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) confirms that it will report its preliminary (unaudited) financial results for the first quarter 2026 and provide a
- 7mo agoPHARPharming Group to participate in April investor conferencesGlobeNewswireLeiden, the Netherlands, April 7, 2026: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) today announced that its management will participate in the following investor conferences in the month of April: 25th Annual
- 7mo agoPHARPharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and olderGlobeNewswireIf approved, Joenja® (leniolisib) would become the first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiencyDecision based
- 7mo agoPHARPharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and olderGlobeNewswireFirst approved treatment in Japan for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)Approval is based on positive Phase III data from multinational and Japanese studies in patients aged 12 years and
- 8mo agoPHARPharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12GlobeNewswireLeiden, the Netherlands, February 26, 2026: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) confirms that it will report its preliminary (unaudited) financial results for the fourth quarter and full year
- 8mo agoPHARPharming Group to present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceGlobeNewswireLeiden, the Netherlands, February 17, 2026: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) today announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference being held
- 9mo agoPHARPharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor DayGlobeNewswireHighlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and mtDNA-driven mitochondrial diseaseIntroduces napazimone
- 9mo agoPHARPharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDSGlobeNewswireLeiden, the Netherlands, February 1, 2026: Pharming Group ((Euronext: PHARM, NASDAQ:PHAR) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to its supplemental
- 10mo agoPHARPharming Group reports preliminary 2025 revenues and announces Investor DayGlobeNewswireLeiden, The Netherlands, January 8, 2026: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) today announced its preliminary, unaudited revenues for the full year 2025 and plans to host a virtual Investor
- 11mo agoPHARPharming Group to participate in Oppenheimer Movers in Rare Disease SummitGlobeNewswireLeiden, the Netherlands, December 8, 2025: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) today announced its participation in the Oppenheimer Movers in Rare Disease Summit on December 11, 2025 in New York City. This
- 1y agoPHARPharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flowGlobeNewswireTotal third quarter 2025 revenues increased by 30% to US$97.3 million, compared to third quarter 2024RUCONEST® third quarter revenue increased by 29% to US$82.2 million, compared to third quarter 2024, reflecting
- 1y agoPHARPharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in LondonGlobeNewswireLeiden, the Netherlands, October 30, 2025: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) announces that Pharming management will participate in the Jefferies Global Healthcare Conference in London, UK, on November
- 1y agoPHARPharming Group to report third quarter 2025 financial results and provide business update on November 6GlobeNewswireLeiden, the Netherlands, October 23, 2025: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) confirms that it will report its preliminary (unaudited) financial results for the third quarter 2025 and provide a business
- 1y agoPHARPharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolioGlobeNewswireLeiden, the Netherlands, October 20, 2025: Pharming Group N.V. ("Pharming" or "the Company") ((Euronext: PHARM, NASDAQ:PHAR) today announced that 12 abstracts have been accepted for presentation at the American College
- 1y agoPHARPharming Group provides update on previously announced G&A expense reduction planGlobeNewswireLeiden, the Netherlands, October 6, 2025: Pharming Group N.V. ("Pharming" or "the Company") ((Euronext: PHARM, NASDAQ:PHAR) today announced the implementation of an organizational restructuring to accelerate the
- 1y agoPHARPharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 yearsGlobeNewswireIf approved, leniolisib will be first and only treatment indicated for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiencyDecision based on positive data from
- 1y agoPHARPharming Group promoted to the Euronext AMX® indexGlobeNewswireLeiden, the Netherlands, September 10, 2025: Pharming Group N.V. ("Pharming" or "the Company") ((Euronext: PHARM, NASDAQ:PHAR) today announced that it has been promoted from the Euronext AScX® (Small Cap) to the
- 1y agoPHARPharming Group to present at the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireLeiden, the Netherlands, September 3, 2025: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) announces that Pharming management will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York
- 1y agoPHARPharming Group appoints Kenneth Lynard as Chief Financial OfficerGlobeNewswireLeiden, the Netherlands, September 2, 2025: Pharming Group N.V. ("Pharming" or "the Company") ((Euronext: PHARM, NASDAQ:PHAR) today announced the appointment of Kenneth Lynard as Chief Financial Officer (CFO), effective
- 1y agoPHARPharming Group to participate in August investor conferenceGlobeNewswireLeiden, the Netherlands, August 4, 2025: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) announces that Pharming's management will participate in the following investor conference in the month of August: Canaccord
- 1y agoPHARPharming Group N.V. (PHAR) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoPHARPharming Group reports second quarter and first half 2025 financial results and provides business updateGlobeNewswireSecond quarter 2025 total revenues increased by 26% to US$93.2 million, compared to the second quarter 2024, driven by strong RUCONEST® and Joenja® revenue growthRUCONEST® second quarter revenue increased
- 1y agoPHARPharming Group to report second quarter and first half 2025 financial results and provide business update on July 31GlobeNewswireLeiden, the Netherlands, July 17, 2025: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) confirms that it will report its preliminary (unaudited) financial results for the second quarter and first half 2025 and provide a
- 1y agoPHARPharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosisGlobeNewswireFor media and investors only Researchers identified variants which may cause activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)Results enable clinical genetic testing labs to appropriately reclassify
- 1y agoPHARPharming Group reports first quarter 2025 financial results and provides business updateGlobeNewswireFirst quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, reflecting
- 1y agoPHARPharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS)GlobeNewswireLeiden, the Netherlands, April 25, 2025: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces the following presentations by the Company or its collaborators at the 2025 Annual Meeting of the
- 1y agoPHARPharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDSGlobeNewswireFor media and investors only Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS Recommended for adult and pediatric patients 12 years of age and older with activated
- 1y agoPHARPharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulationGlobeNewswireMulti-center clinical trial includes sites located in the US, UK and EU Second Phase II clinical trial studying leniolisib for additional primary immunodeficiencies (PIDs) CVID patients demonstrate clinical
- 1y agoPHARPharming Group reports fourth quarter and full year 2024 financial results and provides business updateGlobeNewswireFull year 2024 total revenues increased by 21% to US$297.2 million and exceeded our guidance, driven by record RUCONEST® revenue and strong Joenja® (leniolisib) growth Fourth quarter 2024 total revenues
- 1y agoPHARPharming Group reports on results of the 2025 Extraordinary General Meeting of ShareholdersGlobeNewswireLeiden, the Netherlands, March 4, 2025: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM
- 1y agoPHARPharming Group to participate in March investor conferenceGlobeNewswireLeiden, the Netherlands, February 28, 2025: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) announces that Pharming's management will participate in the following investor conference in the month of March: 37th Annual
- 1y agoPHARPharming Group to report fourth quarter and full year 2024 financial results on March 13GlobeNewswireLeiden, the Netherlands, February 27, 2025: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year 2024 financial results, for the period ended